PMC:7204657 / 81-1032 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"22","span":{"begin":69,"end":73},"obj":"Gene"},{"id":"23","span":{"begin":232,"end":240},"obj":"Species"},{"id":"24","span":{"begin":667,"end":675},"obj":"Species"},{"id":"25","span":{"begin":834,"end":842},"obj":"Species"},{"id":"26","span":{"begin":38,"end":49},"obj":"Chemical"},{"id":"27","span":{"begin":181,"end":192},"obj":"Chemical"},{"id":"28","span":{"begin":349,"end":360},"obj":"Chemical"},{"id":"29","span":{"begin":516,"end":527},"obj":"Chemical"},{"id":"30","span":{"begin":749,"end":760},"obj":"Chemical"},{"id":"31","span":{"begin":853,"end":864},"obj":"Chemical"},{"id":"32","span":{"begin":162,"end":170},"obj":"Disease"},{"id":"33","span":{"begin":223,"end":231},"obj":"Disease"},{"id":"34","span":{"begin":421,"end":441},"obj":"Disease"},{"id":"35","span":{"begin":446,"end":466},"obj":"Disease"},{"id":"36","span":{"begin":581,"end":599},"obj":"Disease"},{"id":"37","span":{"begin":643,"end":657},"obj":"Disease"},{"id":"38","span":{"begin":658,"end":666},"obj":"Disease"},{"id":"39","span":{"begin":900,"end":914},"obj":"Disease"}],"attributes":[{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"Gene:3569"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"Tax:9606"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"Tax:9606"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:9606"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"MESH:C502936"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:C502936"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"MESH:C502936"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"MESH:C502936"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"MESH:C502936"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:C502936"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:C000657245"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:C000657245"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:D001172"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:D013700"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"MESH:D003141"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:D016638"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:C000657245"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:D004238"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown. Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis. Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients. Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2]. The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":83,"end":91},"obj":"Body_part"},{"id":"T3","span":{"begin":113,"end":121},"obj":"Body_part"},{"id":"T4","span":{"begin":452,"end":456},"obj":"Body_part"},{"id":"T5","span":{"begin":762,"end":772},"obj":"Body_part"},{"id":"T6","span":{"begin":808,"end":818},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma7199"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma7199"}],"text":"Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown. Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis. Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients. Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2]. The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":162,"end":170},"obj":"Disease"},{"id":"T4","span":{"begin":223,"end":231},"obj":"Disease"},{"id":"T5","span":{"begin":421,"end":441},"obj":"Disease"},{"id":"T6","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T7","span":{"begin":446,"end":466},"obj":"Disease"},{"id":"T8","span":{"begin":457,"end":466},"obj":"Disease"},{"id":"T9","span":{"begin":581,"end":599},"obj":"Disease"},{"id":"T10","span":{"begin":658,"end":666},"obj":"Disease"},{"id":"T11","span":{"begin":762,"end":784},"obj":"Disease"},{"id":"T12","span":{"begin":808,"end":830},"obj":"Disease"},{"id":"T13","span":{"begin":900,"end":914},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005578"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0008538"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0043494"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0006807"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0006807"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0004235"}],"text":"Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown. Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis. Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients. Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2]. The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T3","span":{"begin":51,"end":52},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":246,"end":247},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":452,"end":456},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T6","span":{"begin":715,"end":716},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T7","span":{"begin":762,"end":772},"obj":"http://purl.obolibrary.org/obo/UBERON_0000160"},{"id":"T8","span":{"begin":762,"end":772},"obj":"http://www.ebi.ac.uk/efo/EFO_0000834"},{"id":"T9","span":{"begin":808,"end":818},"obj":"http://purl.obolibrary.org/obo/UBERON_0000160"},{"id":"T10","span":{"begin":808,"end":818},"obj":"http://www.ebi.ac.uk/efo/EFO_0000834"},{"id":"T11","span":{"begin":915,"end":918},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T12","span":{"begin":933,"end":934},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown. Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis. Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients. Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2]. The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":38,"end":49},"obj":"Chemical"},{"id":"T2","span":{"begin":69,"end":71},"obj":"Chemical"},{"id":"T4","span":{"begin":181,"end":192},"obj":"Chemical"},{"id":"T5","span":{"begin":516,"end":527},"obj":"Chemical"},{"id":"T6","span":{"begin":749,"end":760},"obj":"Chemical"},{"id":"T7","span":{"begin":853,"end":864},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A3","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown. Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis. Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients. Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2]. The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":0,"end":171},"obj":"Sentence"},{"id":"T5","span":{"begin":172,"end":348},"obj":"Sentence"},{"id":"T6","span":{"begin":349,"end":467},"obj":"Sentence"},{"id":"T7","span":{"begin":468,"end":676},"obj":"Sentence"},{"id":"T8","span":{"begin":677,"end":789},"obj":"Sentence"},{"id":"T9","span":{"begin":790,"end":951},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown. Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis. Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients. Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2]. The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T2","span":{"begin":113,"end":138},"obj":"Phenotype"},{"id":"T3","span":{"begin":421,"end":441},"obj":"Phenotype"},{"id":"T4","span":{"begin":457,"end":466},"obj":"Phenotype"},{"id":"T5","span":{"begin":762,"end":784},"obj":"Phenotype"},{"id":"T6","span":{"begin":808,"end":830},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0001370"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0012089"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0031368"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0031368"}],"text":"Zhang et al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown. Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis. Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients. Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2]. The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2]."}